We evaluated safety and efficacy of imatinib (600 mg) in 36 c-KIT+ acute myeloid leukemia patients not amenable to receive conventional chemotherapy. No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5-44+). Non-hematologic toxicity was overall mild.
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study / Piccaluga PP; Malagola M; Rondoni M; Arpinati M; Paolini S; Candoni A; Fanin R; Messa E; Pirrotta MT; Lauria F; Visani G; Alberti D; Rancati F; Vinaccia V; Russo D; Saglio G; Baccarani M; Martinelli G.. - In: HAEMATOLOGICA. - ISSN 0390-6078. - STAMPA. - 92:(2007), pp. 1721-1722. [10.3324/haematol.11345]
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study.
PICCALUGA, PIER PAOLO;Rondoni M;PAOLINI, STEFANIA;BACCARANI, MICHELE;MARTINELLI, GIOVANNI
2007
Abstract
We evaluated safety and efficacy of imatinib (600 mg) in 36 c-KIT+ acute myeloid leukemia patients not amenable to receive conventional chemotherapy. No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5-44+). Non-hematologic toxicity was overall mild.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
